Dr. Warmuth continued, " In parallel with the progress made with our clinical programs, we were proud to see fundamental results from our QuEEN™ discovery engine featured in Science, highlighting Monte Rosa's leadership applying proprietary AI/ML techniques to the discovery of molecular glue degraders, dramatically expanding the addressable protein target space as well as the chemical space for MGDs to address these targets. These advances underscore the broad potential applications of the platform and our ability to create long-term value through focused pipeline execution and strategic collaborations." RECENT HIGHLIGHTS MRT-6160, VAV1-directed MGD for immune-mediated conditions MRT-8102, NEK7-directed MGD for inflammatory diseases driven by IL-1β and the NLRP3 inflammasome MRT-2359, GSPT1-directed MGD for MYC-driven solid tumors Cyclin E1 and CDK2-directed MGD programs for treatment of solid tumors QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine ANTICIPATED UPCOMING MILESTONES AND DEVELOPMENT PRIORITIES SECOND QUARTER 2025 FINANCIAL RESULTS Collaboration revenue: Collaboration revenue for the second quarter of 2025 was $23.2 million, compared to $4.7 million for the quarter ended June 30, 2024.